The Pharmaceutical Licensing Outlook: A strategic guide to effective deal-making and profitable partnerships
Laura Wood <laura.wood <at> researchandmarkets.com>
2003-03-30 07:39:24 GMT
Dear Pharmaceuticals Executive,
I enclose details of our latest pharmaceutical licensing report.
Several factors have combined to transform the role of licensing in the pharmaceutical industry - the
reconfiguration of the value chain, ongoing global consolidation and M&A and plummeting R&D
productivity. In response, licensing has moved away from its roots as a transaction for intellectual
property rights, emerging as a key value driver. Industry leaders now recognise licensing as a strategic
mechanism through which they can achieve their corporate objectives. The Pharmaceutical Licensing
Outlook identifies and examines current best practice in licensing. Using a blend of market analysis,
case studies and executive interviews, the author provides a comprehensive guide to how best to maximize
the returns on licensing activity. Equally valuable for pharmaceutical companies, biotechnology
companies and technology providers, this groundbreaking report offers both practical and strategic
analysis, including a detailed evaluation of successful deal-making.
For a complete index of this report click on http://www.researchandmarkets.com/reports/4621
Report Index:
Table of Contents
The Pharmaceutical Licensing Outlook: A strategic guide to effective deal-making and profitable partnerships
Executive Summary 10
The Licensing Era 10
Licensing Trends 11
Implementing Strategic Objectives 12
Sophisticated Deal-Making 13
Creating Effective Partnerships 14
Licensing Strategy 15
(Continue reading)